Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
GlobalData on MSN11h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trialShionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
Flu is a viral infection affecting the nose, throat and lungs, mostly during the winter months. It is far worse than an ...
3hon MSN
More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback